Severe osteoporosis: Principles for pharmacological therapy in Mexico

Clark, Patricia; Rivera, Fernando Carlos; Méndez-Sánchez, Lucía; Gutiérrez, Carlos; Vargas-Neri, Jessica Liliana; Vázquez, Sandra Miriam Carrillo; Friedmann, D. X. Xibille; Ceballos, Ariana Alvarado; Zepeda, José Manuel Aguilera; Cárdenas, Víctor Mercado; Amengol, Hilario Ávila

doi:10.1016/j.reumae.2019.04.003

Cited by 1 publication

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our model compared two arms: In the first arm, patients received romosozumab 210 mg monthly for 12 months, and were then sequenced to denosumab, 60 mg every six months (romosozumab/denosumab). In the second arm, patients received teriparatide 20 μg daily for 24 months, sequenced to denosumab, 60 mg every six months (teriparatide/denosumab) The choice of these comparators relies on current guidelines for osteoporosis management in Mexico (13). Romosozumab was administered for one year (consistent with the ARCH and FRAME trials and the product label).…”

Section: Methodsmentioning

confidence: 99%

“…The copyright holder for this preprint this version posted February 18, 2024. ; https://doi.org/10.1101/2024.02. 16.24302926 doi: medRxiv preprint 3 consensus statement in Mexico, teriparatide and denosumab were recommended as treatment options for severe osteoporosis (13). Furthermore, until 2022 teriparatide was the only therapy approved for reimbursement in patients with severe postmenopausal osteoporosis at very high risk of fracture (14).…”

Section: (Which Was Not Certified By Peer Review)mentioning

confidence: 99%

“…The choice of these comparators relies on current guidelines for osteoporosis management in Mexico (13). Romosozumab was administered for one year (consistent with the ARCH and FRAME trials and the product label).…”

Section: Comparatorsmentioning

confidence: 99%

“…Severe or established osteoporosis is diagnosed when a previous fracture is present and bone mineral density (BMD), measured by dual-energy X-ray absorptiometry (DXA), is -2.5 standard deviations or more below the mean value of a health young adult (12). According to a recent 3 consensus statement in Mexico, teriparatide and denosumab were recommended as treatment options for severe osteoporosis (13). Furthermore, until 2022 teriparatide was the only therapy approved for reimbursement in patients with severe postmenopausal osteoporosis at very high risk of fracture (14).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Cost-effectiveness of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

Diaz Martinez,

Aubry de Maraumont,

Natty Sánchez

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk of fractures in Mexican women. Methods: A Markov model was used to assess the relative cost effectiveness of 1 year of romosozumab versus 2 years of teriparatide, both sequenced to denosumab for a total treatment duration of 5 years. Outcomes for a cohort of women with a mean age of 74 years, a T-score -2.5 and a previous fragility fracture were simulated over a lifetime horizon. The analysis was conducted from the perspective of the Mexican healthcare system and used a discount rate of 5% per annum. To inform relative fracture incidence, the bone mineral density (BMD) advantage of romosozumab over teriparatide was translated into relative risks of fracture, using relationships provided by a meta-regression of osteoporosis therapy trials. Outcomes were assessed in terms of lifetime costs (2023 Mexican pesos), quality-adjusted life years (QALYs) and life-years gained (LYs). Results: Base case results showed that, compared with teriparatide/ denosumab, romosozumab/ denosumab reduced costs by $51,363 MXN per patient and yielded 0.03 additional QALYs and 0.01 LYs. Scenario analyses and probabilistic sensitivity analyses confirmed that results are robust to uncertainty in model assumptions and inputs. Conclusions: Results show that romosozumab/ denosumab produces greater health benefits at a lower total cost than teriparatide/ denosumab.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: (Which Was Not Certified By Peer Review)mentioning

confidence: 99%

Section: Comparatorsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cost-effectiveness of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

Diaz Martinez,

Aubry de Maraumont,

Natty Sánchez

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Severe osteoporosis: Principles for pharmacological therapy in Mexico

Cited by 1 publication

References 30 publications

Cost-effectiveness of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

Cost-effectiveness of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

Contact Info

Product

Resources

About